Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of orismilast in adults with moderate to severe atopic dermatitis
2021-006707-15Phase 2Completed
- Sponsor
- UNION therapeutics
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of orismilast in atopic dermatitis (AD) (5 arms), sponsored by UNION therapeutics. Primary endpoint: Percentage change in Eczema Area and Severity Index from baseline at Week 16. Started Feb 2022; status: completed.
02
Drugs
orismilast
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2021-006707-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006707-15.